Skip to content

Insights

International Investigations Global Anti-Corruption Summary

International Investigations Global Anti-Corruption Summary

December 31, 2013 Commentary

Attachments
International Investigations Global Anti-Corruption

Sion Richards

Practice Leader Global Disputes

London + 44.20.7039.5139

srichards@jonesday.com
Practice: Global Disputes
Sheila L. Shadmand

Partner-in-Charge Middle East & Africa Region

Dubai + 971.4.709.8408

slshadmand@jonesday.com
Practice: Global Disputes
Hank Bond Walther

Partner

Washington + 1.202.879.3432

hwalther@jonesday.com
Practice: Investigations & White Collar Defense
Peter J. Wang

Partner

Hong Kong + 852.3189.7211

pjwang@jonesday.com
Practice: Global Disputes
Henry Klehm III

Practice Leader Securities Litigation & SEC Enforcement

New York + 1.212.326.3706

hklehm@jonesday.com
Practice: Securities Litigation & SEC Enforcement
Steven W. Fleming

Partner

Sydney + 61.2.8272.0538

sfleming@jonesday.com
Practice: Global Disputes
Jerry C. Ling

Partner

San Francisco + 1.415.875.5890

jling@jonesday.com
Practice: Cybersecurity, Privacy & Data Protection
Hiromitsu Miyakawa

Partner-in-Charge Tokyo

Tokyo + 81.3.6800.1828

hmiyakawa@jonesday.com
Practice: Antitrust & Competition Law
Bénédicte Graulle

Partner

Paris + 33.1.56.59.46.75

bgraulle@jonesday.com
Practice: Investigations & White Collar Defense
Dr. Ralf Recknagel

Of Counsel

Düsseldorf + 49.211.5406.5500

rrecknagel@jonesday.com
Practice: M&A
Fahad A. Habib

Partner

San Francisco + 1.415.875.5761

fahabib@jonesday.com
Practice: Global Disputes

You May Also Be Interested In

April 02, 2025 Newsletters

Blurring the Line Between the Dry and Wet Lab: Joint Inventorship in AI-Assisted Life Science Inventions

April 02, 2025 Newsletters

Constitutional Challenges to Inflation Reduction Act Head to Courts of Appeals

April 02, 2025 Newsletters

Earnouts in M&A Transactions: Recent Decisions From Delaware

April 02, 2025 Newsletters

EU Markets Become More Accessible to Small and Medium-Sized Enterprises Thanks to Changes to the EU Prospectus Regulation: A Welcome Development for Companies Active in the Medical Sector